Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review

CONCLUSION: Atezolizumab/bevacizumab treatment might exacerbate portal hypertension. Careful monitoring and management should be considered during treatment.PMID:38565487 | DOI:10.1016/j.jfma.2024.03.019

Source: Cancer Control - April 2, 2024 Category: Cancer & Oncology Authors: Tung-Yen Lin Tung-Hung Su Source Type: research